Jpmorgan Chase & CO Arrowhead Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,315,705 shares of ARWR stock, worth $46.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,315,705
Previous 2,638,063
12.22%
Holding current value
$46.5 Million
Previous $75.4 Million
20.23%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding ARWR
# of Institutions
291Shares Held
91.6MCall Options Held
1.33MPut Options Held
549K-
Black Rock Inc. New York, NY15.7MShares$315 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$245 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$178 Million3.15% of portfolio
-
State Street Corp Boston, MA5.84MShares$117 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$83 Million2.11% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.12B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...